Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debashis Sarker

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Advances in Cancer Research|December 13, 2006
Pharmacodynamic biomarkers for molecular cancer therapeuticsDebashis Sarker, Paul Workman
Translational Oncogenomics|February 27, 2016
Pharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsDebra H Josephs, Debashis Sarker
Future Oncology (London, England)|January 21, 2016
Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?Georgios Oikonomopoulos, Preetha Aravind, Debashis Sarker
Future Oncology (London, England)|March 7, 2018
PAK4 pathway as a potential therapeutic target in pancreatic cancerKiruthikah Thillai, Debashis Sarker, Claire Wells
Biomarkers in Medicine|May 19, 2010
Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug developmentDebashis Sarker, Simon Pacey, Paul Workman
Immunopharmacology and Immunotoxicology|October 17, 2015
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cellsDoraid Alrifai, Debashis Sarker, John Maher
World Journal of Gastrointestinal Oncology|February 25, 2016
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Kiruthikah Thillai, Paul Ross, Debashis Sarker
Clinical Medicine (London, England)|January 25, 2023
Next-generation sequencing and molecular therapyCienne Morton, Debashis Sarker, Paul Ross
Oncotarget|October 20, 2018
Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agentsEmma J Jordan, James Spicer, Debashis Sarker
Asian Social Work and Policy Review|June 6, 2022
"We'll starve to death": The consequences of COVID-19 over the lives of poor people with disabilities in rural NepalDebashis Sarker, Sanjana Shrestha, Santosh Kumar Baidhya Tamang
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Advances in Cancer Research|December 13, 2006
Pharmacodynamic biomarkers for molecular cancer therapeuticsDebashis Sarker, Paul Workman
Translational Oncogenomics|February 27, 2016
Pharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsDebra H Josephs, Debashis Sarker
Future Oncology (London, England)|January 21, 2016
Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?Georgios Oikonomopoulos, Preetha Aravind, Debashis Sarker
Future Oncology (London, England)|March 7, 2018
PAK4 pathway as a potential therapeutic target in pancreatic cancerKiruthikah Thillai, Debashis Sarker, Claire Wells
Biomarkers in Medicine|May 19, 2010
Use of pharmacokinetic/pharmacodynamic biomarkers to support rational cancer drug developmentDebashis Sarker, Simon Pacey, Paul Workman
Immunopharmacology and Immunotoxicology|October 17, 2015
Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cellsDoraid Alrifai, Debashis Sarker, John Maher
World Journal of Gastrointestinal Oncology|February 25, 2016
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Kiruthikah Thillai, Paul Ross, Debashis Sarker
Clinical Medicine (London, England)|January 25, 2023
Next-generation sequencing and molecular therapyCienne Morton, Debashis Sarker, Paul Ross
Oncotarget|October 20, 2018
Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agentsEmma J Jordan, James Spicer, Debashis Sarker
Asian Social Work and Policy Review|June 6, 2022
"We'll starve to death": The consequences of COVID-19 over the lives of poor people with disabilities in rural NepalDebashis Sarker, Sanjana Shrestha, Santosh Kumar Baidhya Tamang
Pageof 8